Hannah Wang

Hannah Wang

Auto-generated profile, based on publicly available information

Hannah Wang

Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2012 in Gut
Verified
Journal Article
Open access
PDF file
NDNiantao Deng
Niantao Deng
LGLiang Kee Goh
Liang Kee Goh
HWHannah Wang
Hannah Wang
KDKakoli Das
Kakoli Das
JTJiong Tao
Jiong Tao
PTPatrick Tan
Patrick Tan
Objective Gastric cancer is a major gastrointestinal malignancy for which targeted therapies are emerging as treatment options. This study sought to identify the most prevalent molecular targets in gastric cancer and to elucidate systematic patterns of exclusivity and co-occurrence among these targets, through comprehensive genomic analysis of a large panel of gastric cancers. Design Using high-resolution single nucleotide polymorphism arrays, copy number alterations were profiled in a panel of 233 gastric cancers (193 primary tumours, 40 cell lines) and 98 primary matched gastric non-malignant samples. For selected alterations, their impact on gene expression and clinical outcome were evaluated. Results 22 recurrent focal alterations (13 amplifications and nine deletions) were identified. These included both known targets (FGFR2, ERBB2) and also novel genes in gastric cancer (KLF5, GATA6). Receptor tyrosine kinase (RTK)/RAS alterations were found to be frequent in gastric cancer. This study also demonstrates, for the first time, that these alterations occur in a mutually exclusive fashion, with KRAS gene amplifications highlighting a clinically relevant but previously underappreciated gastric cancer subgroup. FGFR2-amplified gastric cancers were also shown to be sensitive to dovitinib, an orally bioavailable FGFR/VEGFR targeting agent, potentially representing a subtype-specific therapy for FGFR2-amplified gastric cancers. Conclusion The study demonstrates the existence of five distinct gastric cancer patient subgroups, defined by the signature genomic alterations FGFR2 (9% of tumours), KRAS (9%), EGFR (8%), ERBB2 (7%) and MET (4%). Collectively, these subgroups suggest that at least 37% of gastric cancer patients may be potentially treatable by RTK/RAS directed therapies.

24 January 2011 in Oncogene
Verified
Journal Article
Open access
JCJ K Cheong
J K Cheong
NHN T Hung
N T Hung
HWH Wang
H Wang
PTP Tan
P Tan
PVP M Voorhoeve
P M Voorhoeve
DVD M Virshup
D M Virshup
Casein kinase 1 delta and epsilon (CK1δ/ ε) are key regulators of diverse cellular growth and survival processes including Wnt signaling, DNA repair and circadian rhythms. Recent studies suggest that they have an important role in oncogenesis. RNA interference screens identified CK1ε as a pro-survival factor in cancer cells in vitro and the CK1δ/ ε-specific inhibitor IC261 is remarkably effective at selective, synthetic lethal killing of cancer cells. The recent development of the nanomolar CK1δ/ ε-selective inhibitor, PF670462 (PF670) and the CK1ε-selective inhibitor PF4800567 (PF480) offers an opportunity to further test the role of CK1δ/ ε in cancer. Unexpectedly, and unlike IC261, PF670 and PF480 were unable to induce cancer cell death. PF670 is a potent inhibitor of CK1δ/ ε in cells; nanomolar concentrations are sufficient to inhibit CK1δ/ ε activity as measured by repression of intramolecular autophosphorylation, phosphorylation of disheveled2 proteins and Wnt/β-catenin signaling. Likewise, small interfering RNA knockdown of CK1δ and CK1ε reduced Wnt/β-catenin signaling without affecting cell viability, further suggesting that CK1δ/ ε inhibition may not be relevant to the IC261-induced cell death. Thus, while PF670 is a potent inhibitor of Wnt signaling, it only modestly inhibits cell proliferation. In contrast, while sub-micromolar concentrations of IC261 neither inhibited CK1δ/ ε kinase activity nor blocked Wnt/β-catenin signaling in cancer cells, it caused a rapid induction of prometaphase arrest and subsequent apoptosis in multiple cancer cell lines. In a stepwise transformation model, IC261-induced killing required both overactive Ras and inactive p53. IC261 binds to tubulin with an affinity similar to colchicine and is a potent inhibitor of microtubule polymerization. This activity accounts for many of the diverse biological effects of IC261 and, most importantly, for its selective cancer cell killing.

15 December 2011 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
COChia Huey Ooi
Chia Huey Ooi
HOHue Kian Oh
Hue Kian Oh
HWHannah Zhu'AI Wang
Hannah Zhu'AI Wang
ATAngie Lay Keng Tan
Angie Lay Keng Tan
JWJeanie Wu
Jeanie Wu
PTPatrick Tan
Patrick Tan
MicroRNAs (miRNAs) are important components of cellular signaling pathways, acting either as pathway regulators or pathway targets. Currently, only a limited number of miRNAs have been functionally linked to specific signaling pathways. Here, we explored if gene expression signatures could be used to represent miRNA activities and integrated with genomic signatures of oncogenic pathway activity to identify connections between miRNAs and oncogenic pathways on a high-throughput, genome-wide scale. Mapping >300 gene expression signatures to >700 primary tumor profiles, we constructed a genome-wide miRNA–pathway network predicting the associations of 276 human miRNAs to 26 oncogenic pathways. The miRNA–pathway network confirmed a host of previously reported miRNA/pathway associations and uncovered several novel associations that were subsequently experimentally validated. Globally, the miRNA–pathway network demonstrates a small-world, but not scale-free, organization characterized by multiple distinct, tightly knit modules each exhibiting a high density of connections. However, unlike genetic or metabolic networks typified by only a few highly connected nodes (“hubs”), most nodes in the miRNA–pathway network are highly connected. Sequence-based computational analysis confirmed that highly-interconnected miRNAs are likely to be regulated by common pathways to target similar sets of downstream genes, suggesting a pervasive and high level of functional redundancy among coexpressed miRNAs. We conclude that gene expression signatures can be used as surrogates of miRNA activity. Our strategy facilitates the task of discovering novel miRNA–pathway connections, since gene expression data for multiple normal and disease conditions are abundantly available. MicroRNAs (miRNAs) are naturally occurring small RNA molecules of ∼22 nucleotides that regulate gene expression. Recent studies have shown that miRNAs can behave as important components of cellular signaling pathways, as pathway regulators or pathway targets. Currently however, only a few miRNAs have been functionally linked to specific signaling pathways, raising the need for novel approaches to accelerate the identification of miRNA–pathway connections. Here, we show that gene expression signatures, previously used to reflect patterns of pathway activation, can also be used to represent miRNA activities. Using this approach, we constructed a genome-wide miRNA–pathway network predicting the associations of 276 human miRNAs to 26 oncogenic pathways. The miRNA–pathway network confirmed a host of previously reported miRNA/pathway associations and uncovered several novel associations that were subsequently experimentally validated. Besides being the first study to conceptually demonstrate that expression signatures can act as surrogates of miRNA activity, our study provides a large database of candidate pathway-modulating miRNAs, which researchers interested in a particular pathway (e.g. Ras, Myc) are likely to find useful. Moreover, because this approach solely employs gene expression, it is immediately applicable to the thousands of microarray data sets currently available in the public domain.